Rock Springs Capital Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Rock Springs Capital Management’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-405,811	Closed	-$568K	–	118
2023 Q3	$568K	Sell	405,811 -341,162	-46%	-$819K	0.02%	110
2023 Q2	$2.26M	Hold	746,973	–	–	0.05%	105
2023 Q1	$4.67M	Hold	746,973	–	–	0.11%	89
2022 Q4	$4.56M	Hold	746,973	–	–	0.11%	91
2022 Q3	$8.93M	Buy	746,973 +128,589	+21%	+$1.68M	0.23%	83
2022 Q2	$7.8M	Buy	618,384 +274,238	+80%	+$2.55M	0.23%	86
2022 Q1	$3.88M	Buy	344,146 +4,300	+1%	+$47.3K	0.1%	111
2021 Q4	$6.02M	Buy	339,846 +6,860	+2%	+$145K	0.14%	113
2021 Q3	$7.67M	Buy	332,986 +1,400	+0.4%	+$30.5K	0.16%	118
2021 Q2	$7.72M	Buy	331,586 +5,200	+2%	+$132K	0.15%	125
2021 Q1	$10.2M	Buy	326,386 +1,700	+0.5%	+$59.2K	0.22%	113
2020 Q4	$12.9M	Buy	+324,686	New	+$13M	0.27%	102

Other funds holding KNTE

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Rock Springs Capital Management's KNTE Position: Q4 2023 in Review

Rock Springs Capital Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2023, closing a stake of 405,811 shares — an estimated $568K sold.

Rock Springs Capital Management first reported a position in KNTE in Q4 2020 and held it in 12 quarters. The position peaked at $12.9M in Q4 2020. 62 funds tracked by Wall St. Rank hold KNTE as of Q4 2023.

Rock Springs Capital Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Rock Springs Capital Management sold 405,811 Kinnate Biopharma Inc. Common Stock shares in Q4 2023, an estimated $568K.
Rock Springs Capital Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 12 quarters.
Rock Springs Capital Management's Kinnate Biopharma Inc. Common Stock position peaked at $12.9M in Q4 2020.
62 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2023.

Based on Rock Springs Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.